statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Co. plc (NASDAQ:PRTA  Get Free Report) shares traded down 2.3% during mid-day trading on Thursday . The company traded as low as $24.53 and last traded at $24.57. 14,520 shares were...

Prothena (NASDAQ:PRTA) Trading Down 2.3%

This price move could be a signal that PRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Prothena (PRTA, $25.1) price may climb as it broke lower Bollinger Band on Mar 18, 2024

This is a Bearish indicator signaling PRTA's price could decline from here. Traders may explore shorting the stock or put options...

Prothena (PRTA, $26.07) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 15, 2024

Prothena (PRTA, $26.48) price may climb as it broke lower Bollinger Band on Mar 14, 2024

Prothena Co. plc (NASDAQ:PRTA  Free Report)  Zacks Research issued their FY2026 EPS estimates for shares of Prothena in a report issued on Thursday, March 7th. Zacks Research analyst...

Prothena Co. plc (NASDAQ:PRTA) to Post FY2026 Earnings of ($4.63) Per Share, Zacks Research Forecasts

This indicator may be signaling that PRTA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Prothena (PRTA, $28.1) entered Downtrend as Momentum indicator drops below 0 level on Mar 11, 2024

Prothena Co. plc (NASDAQ:PRTA  Get Free Report) has been assigned a consensus recommendation of Moderate Buy from the nine research firms that are covering the firm...

Prothena Co. plc (NASDAQ:PRTA) Receives $69.63 Consensus Price Target from Analysts

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Volume	653,662.00
52-Wk High	$79.38
52-Wk Low	$19.65

PRTA Prothena Corporation plc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community